ch and
pharmaceutical industry relationships. P&GP is committed to leveraging this
model to build brands to address unmeet needs in the areas of
gastrointestinal, musculoskeletal and women's health. The P&GP community
consists of more than 3,000 employees working in over 22 countries
worldwide. For more information on P&GP and its prescription product
portfolio, please visit
http://www.pgpharma.com
Three billion times a day, P&G brands touch the lives of people around
the world. P&G has one of the strongest portfolios of trusted brands in
consumer health and wellness, including Align(R), Always(R), Crest(R),
Metamucil(R), Oral-B(R), Pepto-Bismol(R), Prilosec OTC(R), Scope(R),
Tampax(R) and Vicks(R), in addition to its other leadership consumer
brands, including Ariel(R), Braun(R), Bounty(R), Charmin(R), Dawn(R),
Downy(R), Duracell(R), Folgers(R), Gillette(R), Head & Shoulders(R),
Iams(R), Lenor(R), Mach3(R), Olay(R), Pantene(R), Pampers(R), Pringles(R),
Tide(R), Wella(R) and Whisper(R). The P&G community consists of more than
135,000 employees working in over 80 countries worldwide. Please visit
http://www.pg.com for the latest news and in-depth information about P&G
and its brands.
About Digestive Disease Week (DDW)
DDW is the largest international gathering of physicians, researchers
and academics in the fields of gastroenterology, hepatology, endoscopy and
gastrointestinal surgery. Jointly sponsored by the American Association for
the Study of Liver Diseases, the American Gastroenterological Association
(AGA) Institute, the American Society for Gastrointestinal Endoscopy and
the Society for Surgery of the Alimentary Tract, DDW takes place May 17-22,
2008, at the San Diego Convention Center, San Diego, CA. The meeting
showcases approximately 5,000 abstracts and hundreds of lectures on the
latest advances in GI research, medicine and technology. Fo
'/>"/>
SOURCE Procter & Gamble Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 Related medicine technology :1.
ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study2.
Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session3.
Data Presented at the American Psychiatric Association (APA) Annual Meeting Demonstrate Iloperidones Efficacy and Safety, With Low Rates of Movement and Metabolic Adverse Events4.
Clinical Data Demonstrates 5-Year Efficacy and Safety of Aquamid(R) in Facial Augmentation5.
Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial6.
SurgiLance Safety Lancet Part of Major HIV Testing Initiative in Sub-Saharan Africa7.
Cardiac Safety Study of Stinger S-200 Published8.
Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma9.
VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program10.
EnVivo Pharmaceuticals Announces Initiation of Clinical Safety and Biomarker Study of Alpha-7 Nicotinic Agonist, EVP-6124, in Patients with Schizophrenia11.
Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure